ranibizumab

Spain

Drugs containing this active substance

  • LUCENTIS 10 MG/ML SOLUTION FOR INJECTION

    It is used in adults to treat various eye diseases that cause vision impairment, such as age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), and retinal vein occlusion (RVO), among others. In premature infants, it is used to treat retinopathy of prematurity (ROP).

    Form: solution for injection

    Active substance Dosage
    ranibizumab 2,3 mg

    ATC: S01L S01LA S01LA04

    Manufacturer: Novartis Europharm Limited

  • It is used in adults to treat various eye diseases that cause vision impairment, such as age-related macular degeneration (AMD), proliferative diabetic retinopathy, macular edema (swelling of the center of the retina), and other retinal lesions.

    Form: solution for injection

    Active substance Dosage
    ranibizumab 1,65 mg

    ATC: S01L S01LA S01LA04

    Manufacturer: Novartis Europharm Limited

  • It is used in adults to treat various eye diseases that cause vision impairment, such as age-related macular degeneration (AMD), proliferative diabetic retinopathy, macular edema (retinal swelling), and other conditions related to the growth of abnormal blood vessels.

    Form: solution for injection

    Active substance Dosage
    ranibizumab 10 mg

    ATC: S01L S01LA S01LA04

    Manufacturer: Midas Pharma Gmbh

  • It is used in adults to treat various eye diseases that cause vision impairment, such as age-related macular degeneration (AMD), proliferative diabetic retinopathy, macular edema (swelling of the retina), and other retinal lesions caused by the growth of abnormal blood vessels.

    Form: solution for injection

    Active substance Dosage
    ranibizumab 2,3 mg

    ATC: S01L S01LA S01LA04

    Manufacturer: Qilu Pharma Spain S.L.

  • It is used in adults to treat various eye diseases that cause vision impairment, such as age-related macular degeneration (AMD), proliferative diabetic retinopathy, macular edema, and other conditions caused by the growth of abnormal blood vessels or swelling in the retina.

    Form: solution for injection

    Active substance Dosage
    ranibizumab 2,3 mg

    ATC: S01L S01LA S01LA04

    Manufacturer: Stada Arzneimittel Ag